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Abstract
Background: Tumor hypoxia is an important factor related to tumor resistance to radiotherapy and chemotherapy.
This study investigated molecules synthesized in colorectal cancer cells during hypoxia to explore the possibility of
developing molecular probes capable of detecting cell death and/or the efficiency of radiotherapy and chemotherapy.
Methods: At first, we incubated two human colorectal adenocarcinoma cell lines SW480 (UICC stage II) and SW620
(UICC stage III) cells in hypoxic (≤2% O2, 93% N2, and 5% CO2) and normoxic conditions (20% O2, 75% N2, and 5%
CO2) for 24 h and 48 h. The relative expression ratio of GLUT1 mRNA in hypoxic conditions was analyzed by RT-PCR.
Ten cancerous tissues collected from human colorectal cancer patients were examined. HIF-1α and HIF-2α levels were
measured to indicate the degree of hypoxia, and gene expression under hypoxic conditions was determined. As a
comparison, HIF-1α, HIF-2α, and GLUT1 levels were measured in the peripheral blood of 100 CRC patients.
Results: Hypoxia-induced lactate was found to be elevated 3.24- to 3.36-fold in SW480 cells, and 3.06- to 3.17-fold in
SW620 cells. The increased relative expression ratio of GLUT1 mRNA, under hypoxic conditions was higher in SW620
cells (1.39- to 1.72-fold elevation) than in SW480 cells (1.24- to 1.66-fold elevation). HIF-1α and HIF-2α levels were
elevated and GLUT1 genes were significantly overexpressed in CRC tissue specimens. The elevated ratio of GLUT1 was
higher in stage III and IV CRC tissue specimens than in the stage I and II (2.97–4.73 versus 1.44–2.11). GLUT1 mRNA
was also increased in the peripheral blood of stage II and III CRC patients as compared to stage I patients, suggesting that
GLUT1 may serve as a hypoxic indicator in CRC patients.
Conclusion: In conclusion, this study demonstrated that GLUT1 has the potential to be employed as a molecular
marker to indicate the degree of hypoxia experienced by tumors circulating in the blood of cancer patients.
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Background
Hypoxia is an important factor in tumor biology as it
plays a critical role in resistance to radiation therapy and
chemotherapy [1,2]. Hypoxia is tightly correlated with
aggressive tumor behavior, including angiogenesis,
aggressiveness, local recurrence, and distant metastasis
[3,4]. Hypoxia appears to be a poor prognostic factor for
several cancers, including colorectal, cervix, head and
neck, and prostate [5-8]. Despite the importance of tumor
oxygenation status in both therapy and prediction of dis-
ease progression, to date, there has been no consensus as
to the best method for the detection of hypoxia [4]. Cur-
rently available techniques are classified broadly into
direct invasive methods, direct non-invasive methods,
and measurement of surrogate endogenous or chemical
markers of tumor oxygenation. Of these methods, the
Eppendorf pO2 histograph is considered the "gold stand-
ard" for determination of intratumoral oxygen tensions,
but this method is invasive [9-11]. Recent studies have
focused on molecular markers of hypoxia. The chemical
hypoxia marker, pimonidazole, and expression of the
endogenous hypoxia markers (carbonic anhydrase IX,
hypoxia-inducible factor 1α, osteopontin, ephrin A1,
galectin-1, and lysyl oxidase) are used to detect hypoxia by
immunohistochemical staining of tumor biopsy tissues
[5,6,12]. Lactate is the end product of glycolysis; and in
1996, Terpstra reported that in vivo measurements of
tumor lactate concentration may provide valuable infor-
mation about tumor metabolism [13]. Our previous study
showed that the glycolytic pathway and glycolysis-related
genes may play an important role in the tumorigenesis of
CRC. Cell line studies identified 8 genes, including
GLUT1, HK1, GPI, GAPD, PGK1, PGK2, ENO2, and
PKM2, that have a high level of expression. Furthermore,
Hypoxia-inducible factor 1 (HIF-1) has been found to tar-
get the transcription of over 60 genes involved in many
aspects of cancer biology, including cell survival, glucose
metabolism, cell invasion and angiogenesis [14]. These
genes might provide a reference to the future clinical diag-
nosis of CRC and the pharmaceutical efficacy of treat-
ment.
In publicly acknowledged clinical experiences with CRC
patients, regular clinical biochemical tests and imaging
studies have been employed as tools for post-surgical fol-
low-up. Of these, carcinoembryonic antigen (CEA) is the
most commonly used tumor marker for the detection of
non-symptomatic recurrence. However, recent studies
have pointed out that the sensitivity of CEA and CA 19-9
are only 30% and 18%, respectively [15]. Although CEA
detection in the serum and tumor tissue of colorectal can-
cer (CRC) patients is the most commonly used marker for
the diagnosis and evaluation of prognosis or recurrence
after treatment, its role remains controversial [16]. In
terms of tools for imaging studies, F-18-fluorodeoxyglu-
cose-positron emission tomography (FDG-PET) can be
utilized for early assessment of the chemotherapy
response in patients with advanced colorectal cancer [17].
However, FDG-PET is a functional testing tool, so other
structural imaging tools, such as computed tomography
(CT) and magnetic resonance imaging (MRI), need to be
employed in conjunction with FDG-PET for more precise
location of the tumor. Moreover, inflammation, activity
of the intestinal tract itself or constipation can often cause
false-positives in FDG-PET studies. Using CT in the preop-
erative staging of colorectal cancer, even if controversial,
may be useful for planning surgery and/or neoadjuvant
therapy [18]. CT is one of the routinely used methods for
detecting local recurrence, but recurrence in the pelvis and
post-surgical fibrosis are hard to differentiate with this
technique. Therefore, there are shortfalls in current meth-
odologies being offered. Both imaging tools and chemo-
therapy have their own inherent inconveniences and
deficiencies, especially in providing evidence for the ther-
apeutic efficacy of target drugs.
According to the report by Weidner et al. [19], active ang-
iogenesis may occur in prostate cancer tissue growing to 2
mm in diameter. In a metastatic state, each gram of tumor
may shed approximately 106 cells into the blood vessel
[20]. Since blood sampling is relatively easy, we wish to
discover a molecular marker that could be used to assess
the hypoxia level of peripheral circulating cancer cells in
the blood specimens of cancer patients. To date, however,
no correlation between the expression levels of these
mRNA markers and the cancer progression stages of CRC
patients has been determined. In the present study, we
investigate the correlation of hypoxia-related genes and
glycolysis-related genes and clinical prognosis in CRC
patients in Taiwan. We present the correlation between
lactate concentrations with hypoxia status in CRC cell
lines under hypoxic conditions; and in parallel, we dem-
onstrate the expression of the transcription factor HIF-1α
and of the GLUT1 (a glucose transporter protein) mRNA
by RT-PCR. We exploited membrane array to quantita-
tively analyze the expression of GLUT1 mRNA markers in
the circulating tumor cells of patients with stage-II and -III
CRC. The aim of this innovative diagnosis technique
established in this study is to achieve early CRC detection
and improve the efficacy of therapies in managing this
malignancy.
Methods
Colorectal cancer cell lines
Two human colorectal adenocarcinoma cell lines, SW480
(UICC stage II) and SW620 (UICC stage III), were
obtained from American-Type Culture Collection (CCL-
228 and CCL-227; ATCC, Rockville, MD, USA) and used
for this study. Cells were maintained in Leibovitz's L-15
medium (Gibco Life Sciences, BRL, Grand Island, NY,BMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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USA) and supplemented with 10% (v/v) fetal bovine
serum (FBS) at 37°C in humidified atmospheric air with-
out CO2 addition. Cell density was maintained in approx-
imately 100,000 cells/mL medium in T-25 flasks
(Corning, NY, USA). When the cells had grown to a con-
fluent monolayer, they were harvested by washing the
dishes once with phosphate-buffered saline (PBS), pH
7.3, and then incubated in PBS containing 0.53 mmol/L
EDTA and 0.05% trypsin (Gibco) for 10–15 min at 37°C.
The trypsinized cells were counted, and cell viability was
assessed by trypan blue dye exclusion. Then, the cells were
incubated for 24 and 48 h under two different oxygenated
conditions (hypoxia: ≤2% O2, 93% N2, 5% CO2; nor-
moxia: 20% O2, 75% N2, 5% CO2).
Lactate concentration measurements
Cells were rinsed twice with phosphate-buffered saline,
fresh medium was added to the cultures with and without
each of the glucose analogs tested (2-Deoxy-D-glucose
(2DG), at the indicated concentrations, and the cells were
incubated at 37°C in humidified atmospheric air without
CO2 addition for 24 and 48 h. Then, the media were col-
lected for lactate concentration determination. The super-
natant was centrifuged three times to yield a final clear
supernatant. Aliquots of the culture medium were
removed for content analysis. The absorbance was meas-
ured at 540 nm with a Multiskan®  EX ELISA Reader
(Thermo Electron Corp., Finland) using a linear range of
standard lactate concentrations according to the proce-
dures recommended by the manufacturer (Trinity Bio-
tech, Jamestown, NY). The intra-assay coefficient of
variation was 1.1%. Samples were analyzed in triplicate.
The relative concentration of lactate was examined after
normoxia and hypoxia incubations for either 24 h or 48
h, respectively.
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
RNA was extracted from colorectal cancer cell lines using
ISOGEN™ (Nippon Gene Co., Ltd., Toyama, Japan) and
QIAmp® RNA Blood Mini Kit (Qiagen Inc., Valencia, CA).
Total RNA (20 μg) was reverse transcribed to cDNA and
two microliters of each of these cDNA samples were used
for each PCR reaction. Two target genes, HIF-1α and
GLUT1, were detected by RT-PCR. Sequences of the oligo-
nucleotide primers were designed according a PCR primer
selection program based on primer 3 at http://
frodo.wi.mit.edu. Also, β-actin primers were added as
internal controls to correct for the differences in total RNA
amounts between the SW480 and SW620 cells. Each RT-
PCR reaction mixture contained 1 × PCR buffer (10
mmol/L Tris-HCL, pH 8.3, 50 mmol/L KCL, 2 mmol/L
MgCl2), 50 μmol/L dNTP, 0.1 μmol/L sense and antisense
primers for target genes, and 0.01 μmol/L sense and anti-
sense primers for β-actin, and 2.5 U Taq DNA polymerase
in a total volume of 50 μL. PCR amplification was carried
out in a GeneAmp 2700 thermocycler (Applied Biosys-
tems, Foster City, CA), under the following conditions:
initial denaturation at 95°C for 5 min; 33–35 cycles at
94°C for 30 s, at 60°C for 30 s, at 72°C for 1 min, and
then at 72°C for 5 min for the final extension. PCR prod-
ucts were analyzed in 3% agarose gel containing 0.5 μg/
mL ethidium bromide. The signals on UV transillumina-
tor for each target gene and β-actin expression levels were
scanned with a computing laser densitometer (Alpha
Inotech, San Leandro, CA, USA) to calculate the relative
mRNA density. Additional File 1 lists the primer
sequences, PCR conditions, and sizes of PCR products.
Tissue and blood samples
Ten CRC patients, ages ranging from 32 to 68 years (mean
age: 51.5 ± 13.1 years), were selected randomly from a
patient group at the Department of Surgery of Kaohsiung
Medical University Hospital between May 2006 and
March 2008. None of these patients had received any pre-
operative radiotherapy or chemotherapy. According to the
prospective protocol, the tumors and all of the lymph
nodes were cut at different levels and embedded in paraf-
fin, and sections were taken for routine H&E staining. Sen-
ior pathologists checked all of these slides and
documented the pathological characteristics of the tumor
and lymph nodes. The tumor stage was defined according
to the criteria of the American Joint Commission on Can-
cer/International Union Against Cancer (AJCC/UICC,
2002). Patients' characteristics are depicted in Additional
File 2. Each tissue sample was snap-frozen in liquid nitro-
gen immediately after surgery, and stored at -80°C.
Between July 2006 and May 2008, peripheral blood sam-
ples of 100 pre-operative CRC patients (mean age: 57.4 ±
13.4 years) were collected for genotype analysis. Five mil-
lilitres of peripheral blood were collected with test tubes
containing anticoagulant sodium citrate from each of the
enrolled patients before receiving any anticancer treat-
ment, e.g., surgery, radiotherapy or chemotherapy. To
avoid the contamination of skin cells, the sampled blood
was taken via an intravenous catheter, and the first few
millilitres of blood were discarded. Total RNA was imme-
diately extracted from the peripheral whole blood, and
then served as templates for cDNA synthesis. Written
informed consent was obtained from all subjects and/or
guardians for the use of their tissue and blood samples.
Tissue and blood acquisition and subsequent use were
approved by the institutional review board of Kaohsiung
Medical University.
Total RNA extraction and first strand cDNA synthesis
Total RNA was extracted from colorectal cancer patient's
tissue and peripheral blood specimens with ISOGEN™
(Nippon Gene, Toyama, Japan) and QIAmp® RNA Blood
Mini Kit (Qiagen Inc., Valencia, CA) according to theBMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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manufacturer's instructions [21]. The RNA concentration
was determined spectrophotometrically on the basis of
absorbance at 260 nm (Beckman, DU800, USA). First-
strand cDNA was synthesized from total RNA using a RT-
PCR kit (Promega Corp., Madison, WI). The reverse tran-
scription was carried out in a reaction mixture consisting
of 1× Transcription Optimized 5× Buffer, 25 μg/ml oligo
(dT)-15mer primer, 100 mmol/L PCR Nucleotide Mix,
200 μmol/L M-MLV Reverse Transcriptase, and 25 μL of
Recombinant RNasin® Ribonuclease Inhibitor (Promega).
The reaction mixtures were incubated at 42°C for longer
than 2 h, heated to 95°C for 5 min, and then stored at -
80°C until analysis. Total RNA (20 μg) was reverse tran-
scribed to cDNA.
Membrane array preparation for hypoxia- and glycolysis-
associated gene expression
The procedure of the membrane-array method for the
detection of CRC-related genes was performed based on
our previous work [22-24]. Visual OMP3 (Oligonucle-
otide Modeling Platform, DNA Software, Ann Arbor, MN)
was used to design probes for each target gene and β-actin,
the latter of which was used as an internal control (Addi-
tional File 3). The probe selection criteria included strong
mismatch discrimination, minimal or no secondary struc-
ture, signal strength at the assay temperature, and lack of
cross-hybridization. The oligonucleotide probes were
then synthesized according to the designed sequences,
purified, and controlled before being grafted onto the
substracts. The newly synthesized oligonucleotide frag-
ments were dissolved in distilled water to a concentration
of 20 mM, applied to a BioJet Plus 3000 nL dispensing sys-
tem (BioDot, Irvine, CA), which blotted the sixteen target
oligonucleotides and TB (Mycobacterium tuberculosis)
and the β-actin control sequentially (0.05 μL per spot and
1.5 mm between spots) on SuPerCharge nylon membrane
(Schleicher and Schuell, Dassel, Germany) in triplicate.
Dimethyl sulfoxide (DMSO) was also dispensed onto the
membrane as a blank control (Figure 1A). After rapid dry-
ing and cross-linking procedures, the preparation of
membrane array for hypoxia- and glycolysis-associated
gene expression was accomplished [25]. A triplicate set of
16 molecular markers of colorectal cancer was blotted on
nylon membrane. In addition, the housekeeping gene was
β-actin while the bacterial gene was derived from Myco-
bacterium tuberculosis. Both served as positive and nega-
tive controls, respectively, and blotted on the membrane.
The membrane array was used to analyze the gene expres-
sion of tumor and normal counterpart tissue in 10 CRC
patients and 100 peripheral blood specimens.
Preparation of digoxigenin-labeled cDNA targets and 
hybridization
First-strand cDNA targets for hybridization were produced
by using SuperScript reverse transcriptase (Gibco-BRL,
Gaithersburg, MD) in the presence of digoxigenin (DIG)-
labeled dUTP (Roche Diagnostics GmbH, Penzberg, Ger-
many). After the pre-hybridization procedures, the gene
chips were subjected to hybridization. The lifts were cov-
ered with Express Hyb Hybridization Solution (BD Bio-
sciences, Palo Alto, CA) containing DIG-11-UTP-labeled
cDNA probes. After the washing and blocking steps, the
arrays were incubated with alkaline phosphatase-conju-
gated anti-digoxigenin antibody (Roche Diagnostics). For
hybridization, the arrays were incubated at 42°C for 12 h
in a humidity chamber. For signal detection, the gene
chips were incubated in chromogen solution containing
nitroblue-tetrazolium and 5-bromo-4-chloro-3-indoyl-
phosphate (NBT/BCIP) for 15 min. The hybridized arrays
were then scanned with an Epson Perfection 1670 flatbed
scanner (SEIKO EPSON Corp., Nagano-ken, Japan). Sub-
sequent quantification analysis of each spot's intensity
was carried out using AlphaEase®  FC software (Alpha
Innotech Corp., San Leandro, CA). Spots consistently car-
rying a factor of two or more were considered as differen-
tially expressed. These array analysis tools facilitated the
measurement of relative gray levels of objects in a uni-
formly spaced array, such as dot blots. A deformable tem-
plate extracted the gene spots and quantified their
expression levels by determining the integrated intensity
of each spot after background subtraction. The fold ratio
for each gene was calculated as follows: spot intensity
ratio = mean intensity of target gene/mean intensity of β-
actin. Figure 1A provides the schematic representation of
the membrane array with 16 target genes, one housekeep-
ing gene (β-actin), one bacterial gene (TB), and the blank
control.
Statistical analysis
All data were analyzed using the Statistical Package for
Social Sciences Version 11.5 software (SPSS Inc., Chicago,
IL). Data are presented as means ± SE, and P values were
determined by unpaired Student's t test. Furthermore, the
two-sided Pearson χ2 test was used to analyze the differ-
ences in the over-expression of the genotypes between dif-
ferent age groups, gender and stages. A P value of less than
0.05 was considered statistically significant.
Results
Correlation between Lactate concentrations with hypoxia 
status
The concentration of lactate is stimulated differently by
hypoxia and normoxia after 24 and 48 h, respectively. Rel-
ative lactate concentration curves of the two colorectal
cancer cell line supernatants, SW480 and SW620, are
shown in Figure 2. The relative elevated lactate concentra-
tions of SW480 cell lines were 3.24-fold (hypoxia/nor-
moxia: 41.63/12.84; after 24 h incubation) and 3.36-fold
(hypoxia/normoxia: 65.70/19.56; after 48 h incubation);
however, lactate was elevated 3.06-fold (hypoxia/nor-BMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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moxia: 30.78/10.05; after 24 h incubation) and 3.17-fold
(hypoxia/normoxia: 70.45/22.23; after 48 h incubation)
in SW620 cell lines.
HIF-1  and GLUT1 mRNA expressions in SW480 and 
SW620 cell lines under normoxia and hypoxia conditions
For the characterization of the molecular effects in
response to hypoxic conditions in all investigated cells,
quantitative RT-PCR analysis of HIF-1α and GLUT1 was
performed. The mRNA levels of the housekeeping gene β-
actin served as the internal control for the normalization
of mRNA levels in experimental samples. Results of RT-
PCR analysis of HIF-1α mRNA and GLUT1 mRNA expres-
sion in SW480 and SW620 cell lines which were incu-
bated for approximately 24 and 48 h respectively in
hypoxia conditions and normoxia conditions are shown
in Figure 3. The relative expression ratios of HIF-1α mRNA
and GLUT1 mRNA under hypoxia were all higher than
normoxia conditions in both two cell lines.
Results of the comparison of the relative HIF-1α mRNA
expression ratio of SW480 and SW620 cell lines between
normoxia and hypoxia conditions are shown in Figure 4.
The relative HIF-1α mRNA expression levels were elevated
while cells were exposed to hypoxia conditions. The rela-
tive HIF-1α mRNA expression ratios of SW480 cell lines
were 1.26-fold (hypoxia/normoxia: 1.36/1.08; after 24 h
incubation) and 2.63-fold (hypoxia/normoxia: 6.37/
2.42; after 48 h incubation); however, 1.43-fold (hypoxia/
normoxia: 1.76/1.23; after 24 h incubation) and 3.32-fold
Schematic representation of membrane array and comparison of gene expression patterns between a human colorectal cancer  patient (Case No. 6) and healthy control Figure 1
Schematic representation of membrane array and comparison of gene expression patterns between a human 
colorectal cancer patient (Case No. 6) and healthy control. (A) Schematic representation of membrane array with 16 
target genes, one housekeeping gene (β-actin), one bacteria gene (TB), and blank control. Sixteen target genes (i.e., GLUT1, 
HK1, GPI, PGK1, PGK2, ENO2, PKM2, uPA, CA9, CA12, TP, bFGF, COX-2, HIF-1α, HIF-2α, and VEGF). The position of the 
correlation of the blank and positive control (β-actin) as well as the negative control (Mycobacterium tuberculosis; TB) in the 
nylon membrane are pointed out by spots. The relevant positions are the red area (β-actin), blue area (blank), green area (TB), 
yellow area (glycolysis-related genes), and pink area (hypoxia-related genes). (B) A triplicate set of 16 molecular markers for 
colorectal cancer was blotted on the nylon membrane. In addition, a housekeeping gene and a bacterial gene serving as positive 
and negative controls, respectively, were also blotted on the membrane.BMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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elevated HIF-1α mRNA expressions (hypoxia/normoxia:
7.63/2.30; after 48 h incubation) were observed in SW620
cell lines.
A comparison of the relative GLUT1 mRNA expression
levels of SW480 and SW620 cell lines between normoxia
and hypoxia conditions is illustrated in Figure 5. The
results showed that the relative GLUT1 mRNA expression
levels were elevated when cells were exposed to hypoxia.
The relative GLUT1 mRNA expression ratio of SW480 cell
lines were 1.24-fold (hypoxia/normoxia: 2.37/1.91; after
24 h incubation) and 1.66-fold (hypoxia/normoxia: 3.89/
2.34; after 48 h incubation). In SW620 cell lines, however,
we observed 1.39-fold (hypoxia/normoxia: 2.48/1.79;
after 24 h incubation) and 1.72-fold elevation of GLUT1
mRNA expression (hypoxia/normoxia: 4.43/2.58; after 48
h incubation).
Glycolysis- and hypoxia-associated gene expressions in 
CRC tissue specimens
We used mRNA membrane array to explore gene expres-
sion profiles in CRC tissues. Seven candidate genes of gly-
colysis-associated genes (i.e., HK1, GPI, PGK1, PGK2,
ENO2, PKM2, and GLUT1) and nine hypoxia-associated
genes (i.e., uPA, CA9, CA12, TP, bFGF, COX-2, HIF-1α,
HIF-2α, and VEGF) were detected in the present study. We
spotted the well-designed oligonucleotide for each candi-
date gene onto nylon membrane for further analysis (Fig-
ure 1). Membrane array analysis was performed on 10
human CRC tissue samples and 10 paired human normal
colorectal tissue samples. Additional File 4 lists the rela-
tive gene expression ratios of colorectal cancer tissues
compared with normal controls.
We found that GLUT1, HIF-1α, and HIF-2α genes pre-
sented 100% overexpression in these 10 CRC tissue sam-
ples. The overexpression rate of the other genes were 60%
in HK1; 70% in GPI and PGK1; 80% in ENO2, PKM2,
uPA, TP, bFGF and VEGF; and 90% in PGK2, CA9, CA12
and COX-2. The overexpression ratios of GLUT1, HIF-1α
and HIF-2α genes in poorly differentiated stage-III and -IV
samples were higher than in well differentiated stage-I and
moderately differentiated stage-II samples (Additional
File 4).
In Figure 1B, we compared the gene expression intensity
ratio obtained by membrane array between human CRC
tissue specimens (Case No. CRC6) and normal control.
The results show the expression ratios for the sixteen
genes, including 1.11 in HK1, 1.17 in GPI, 1.94 in PGK1,
2.24 in PGK2, 2.75 in ENO2, 2.59 in PKM2, 4.73 in
GLUT1, 2.08 in uPA, 2.17 in CA9, 3.07 in CA12, 2.12 in
TP, 3.04 in bFGF, 2.09 in COX-2, 3.55 in HIF-1α, 3.73 in
HIF-2α, and 1.78 in VEGF. In the poorly differentiated
Relative lactate concentration curves of two colorectal can- cer cell lines Figure 2
Relative lactate concentration curves of two colorec-
tal cancer cell lines. Supernatants from the two colorectal 
cancer cell lines SW480 and SW620. Control specimens 
were acquired from the supernatants of culture medium 
only. The concentrations of lactate were examined after 
incubation for 24 h and 48 h in hypoxia and normoxia condi-
tions. Relative elevated lactate concentrations of SW480 cell 
lines were 3.24-fold (hypoxia/normoxia: 41.63/12.84; after 24 
h incubation) and 3.36-fold (hypoxia/normoxia: 65.70/19.56; 
after 48 h incubation); however, there were 3.06-fold 
(hypoxia/normoxia: 30.78/10.05; after 24 h incubation) and 
3.17-fold (hypoxia/normoxia: 70.45/22.23; after 48 h incuba-
tion) elevated lactate in SW620 cell lines. Values are means ± 
SD of 3 independent experiments with triplicate dishes.
RT-PCR analysis of HIF-1α and GLUT1 mRNA expression in  SW480 and SW620 cell lines under normoxia and hypoxia  conditions Figure 3
RT-PCR analysis of HIF-1α and GLUT1 mRNA 
expression in SW480 and SW620 cell lines under 
normoxia and hypoxia conditions. Results of RT-PCR 
analysis of HIF-1α mRNA and GLUT1 mRNA expression in 
SW480 and SW620 cell lines incubated for approximately 24 
and 48 h in hypoxia and normoxia conditions. The relative 
expression ratio of HIF-1α mRNA and GLUT1 mRNA under 
hypoxia conditions were all higher than normoxia in both cell 
lines. The mRNA levels of the housekeeping gene β-actin 
served as the internal control for the normalization of 
mRNA levels in experimental samples. The measured values 
in a series were normalized to the β-actin signal of the 
respective control.BMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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stage-IV colon adenocarcinoma specimen (Case No.
CRC6), we found that GLUT1 had the highest overexpres-
sion of the glycolysis-pathway-associated genes (Figure
6).
Glycolysis- and hypoxia-associated gene expressions in the 
peripheral blood specimens of 100 CRC patients
We used mRNA membrane array to explore gene expres-
sion profiles in CRC peripheral blood specimens. The
highest overexpressed gene of the glycolysis-pathway-
associated genes, GLUT1, and five hypoxia-associated
genes (i.e., CA9, CA12, COX-2, HIF-1α, and HIF-2α) were
detected in the present study. The overexpression rates of
all five genes were higher than 90% in human CRC tissue
samples. The correlation between mRNA expressions and
clinicopathological features of CRC patients are shown in
Additional File 5.
No statistical correlations between CA9, CA12, COX-2,
HIF-1α, and HIF-2α overexpression and age or sex (P >
0.05; Additional File 5) were found. However, advanced
cancer stage was significantly related to GLUT1 overex-
pression (P = 0.004). The GLUT1 overexpression rates for
Comparison of the relative HIF-1α mRNA expression ratio  of SW480 and SW620 cell lines between normoxia and  hypoxia conditions Figure 4
Comparison of the relative HIF-1α mRNA expres-
sion ratio of SW480 and SW620 cell lines between 
normoxia and hypoxia conditions. The results showed 
that the relative HIF-1α mRNA expression levels were ele-
vated in cells exposed to hypoxia conditions. The relative 
HIF-1α mRNA expression ratio of SW480 cell lines were 
1.26-fold (hypoxia/normoxia: 1.36/1.08; after 24 h incuba-
tion) and 2.63-fold (hypoxia/normoxia: 6.37/2.42; after 48 h 
incubation); however, there was a 1.43-fold (hypoxia/nor-
moxia: 1.76/1.23; after 24 h incubation) and 3.32-fold ele-
vated HIF-1α mRNA expression (hypoxia/normoxia: 7.63/
2.30; after 48 h incubation) in SW620 cell lines. The control 
groups were incubated in humidified atmospheric air without 
the addition of CO2. Values shown are means ± SD of 3 inde-
pendent experiments with triplicate specimens.
Comparison of the relative GLUT1 mRNA expression levels  of SW480 and SW620 cell lines between normoxia and  hypoxia conditions Figure 5
Comparison of the relative GLUT1 mRNA expres-
sion levels of SW480 and SW620 cell lines between 
normoxia and hypoxia conditions. The results showed 
that the relative GLUT1 mRNA expression level was ele-
vated in cells exposed to hypoxia. The relative GLUT1 
mRNA expression ratio of SW480 cell lines were 1.24-fold 
(hypoxia/normoxia: 2.37/1.91; after 24 h incubation) and 
1.66-fold (hypoxia/normoxia: 3.89/2.34; after 48 h incuba-
tion); however, there was a 1.39-fold (hypoxia/normoxia: 
2.48/1.79; after 24 h incubation) and a 1.72-fold elevated 
GLUT1 mRNA expression (hypoxia/normoxia: 4.43/2.58; 
after 48 h incubation) in SW620 cell lines. The control 
groups were incubated in humidified atmospheric air without 
the addition of CO2. Values shown are means ± SD of 3 inde-
pendent experiments with triplicate specimens.
Comparison of the hypoxia- and glycolysis-associated gene  expression intensity between human CRC (Case No. 6) and  normal tissue Figure 6
Comparison of the hypoxia- and glycolysis-associated 
gene expression intensity between human CRC 
(Case No. 6) and normal tissue. The results showed the 
relative expression ratio of sixteen genes. The overexpres-
sion of GLUT1, HIF-1α, and HIF-2α are presented in these 
human colorectal cancer tissue samples.BMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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UICC stage I, II and III were 33.3%, 85.9% and 86.5%,
respectively. The risk of GLUT1 overexpression was higher
in stage II and III than in stage I (RR: 12.482; P = 0.001).
Discussion
Colorectal cancer (CRC) is a leading cause of morbidity
and mortality in Europe and the United States [26-28]. As
several investigators have reported, approximately 40% to
50% of CRC patients who undergo a supposedly curative
resection, subsequently develop metastatic disease and
die of their disease within 5 years [29,30]. Despite the
efforts to clarify the correlation between CRC prognosis
and gene expression by previous investigators, the results
have been equivocal [31,32].
Hypoxia has a strong influence on the metabolism of cells
and, as a consequence, on the physiology and vasculature
of solid tumors. One key regulator of hypoxia – the tran-
scription factor HIF-1 – has been shown to be involved in
the up-regulation of many genes which are involved in
erythropoiesis, angiogenesis, glycolysis, glucose transport,
and several other functions [33,34]. Apart from activating
HIF-1, hypoxia stimulates a great variety of cellular
responses. Many signaling pathways that are deregulated
in cancer promote HIF-1 activity.
The main objective of this study was to discover a molec-
ular marker that could be used to assess the hypoxia level
of peripheral circulating cancer cells in the blood speci-
mens of cancer patients by a well-established membrane
array method [22,25,35]. The mRNA markers employed
included seven glycolysis-associated genes (i.e., HK1, GPI,
PGK1, PGK2, ENO2, PKM2, and GLUT1) and nine
hypoxia-associated genes (i.e., uPA, CA9, CA12, TP, bFGF,
COX-2, HIF-1α, HIF-2α, and VEGF). The data obtained
revealed that HIF-1α and HIF-2α are the predominant
overexpressed hypoxia-associated genes found in CRC tis-
sues. There was 100% mRNA overexpression of GLUT1
gene in our human CRC specimens that paralleled the
hypoxic mRNA overexpression (HIF-1α). GLUT1 gene
was the significant up-regulated glycolysis-associated gene
in hypoxic CRC cells.
Malignant cells are known to have accelerated metabo-
lism, high glucose requirements, and increased glucose
uptake. Although several studies have demonstrated that
cancer cells have increased glycolytic activity in many
malignant diseases in vivo and in vitro [36-39], participa-
tion of the glycolytic pathway and glycolysis-associated
genes in tumorigenesis of human CRC has yet to be eluci-
dated. In our study, we concluded that hypoxia can stim-
ulate glycolysis of CRC cells. The relative lactate
concentration under hypoxic conditions is 3.24- to 3.36-
fold elevated in SW480 cells, and 3.06- to 3.17-fold in
SW620 cells when compared with normoxic conditions,
observed up to 48 h.
Of late, interest in glucose uptake by tumor cells has
increased. Facilitative glucose transporters (GLUTs) allow
the energy-independent transport of glucose across the
hydrophobic cell membrane, downwards along its con-
centration gradient. Each of the glucose transporter pro-
teins possesses different affinities for glucose and other
hexoses, such as fructose. GLUT1, GLUT3, and GLUT4
have a high affinity for glucose, allowing transport of glu-
cose at a high rate under normal physiological conditions
[40,41]. GLUT1 is present at variable levels in many tis-
sues and is believed to be responsible for basal glucose
uptake [42,43]. We performed RT-PCR analysis of HIF-1α
and GLUT1 mRNA expressions in SW480 and SW620
CRC cell lines. The relative expression ratio of HIF-1α
mRNA and GLUT1 mRNA in hypoxic conditions was
higher than in normoxic conditions. In the hypoxic con-
dition, HIF-1α mRNA expression ratio were 1.26- to 2.63-
fold elevated in SW480 cells and 1.43- to 3.32-fold higher
in SW620 cells. GLUT1 mRNA expression ratios were sim-
ilarly proportional to the hypoxic conditions with 1.24- to
1.66-fold elevation in SW480 cells and 1.39- to 1.72-fold
elevation in SW620 cells. SW480 and SW620 represented
the two human colorectal adenocarcinoma cell lines of
UICC II and UICC III, respectively. We found that GLUT1
mRNA expression could be stimulated by hypoxia, and
the expression is more predominant in the advanced CRC
cell lines (UICC III) in vitro. Malignant cells exhibit
increased glycolytic metabolism. Warburg first established
a correlation between aggressive tumor phenotypes and
elevated glycolysis when he observed that many tumors
produce excessive lactate in the presence of oxygen [44].
Previous reports observed that suppression of facilitative
GLUT1 mRNA could suppress the growth of gastric cancer
cell line (MKN45) [45]. Thus, an increased uptake of glu-
cose provides energy to enhance cell synthesis. This might
be an important aspect of malignant transformation and
uncontrolled cell growth.
GLUT1 expression was also elevated in other tumor enti-
ties. In 2007, Shao et al. suggested that the abnormal
expression of GLUT1 may perhaps participate in serous
ovarian tumor occurrence and development and may be
considered as a marker reflecting tumor malignant behav-
iour [46]. Bone and soft tissue sarcomas with GLUT1 over-
expression showed significantly poor OS compared with
those without GLUT1 overexpression (P = 0.029) accord-
ing to Endo et al. [47]. In 2008, Ciampi et al. reported that
GLUT1 and GLUT3 were the most important glucose
transporters in the thyroid tumoral cells. In particular,
GLUT1 was the most prevalent in less-differentiated cells,
while GLUT3 was the most prevalent in well-differenti-BMC Cancer 2009, 9:241 http://www.biomedcentral.com/1471-2407/9/241
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ated cells [48]. HIF-1α was increasingly expressed from
early stages through advanced stages of endometrioid ade-
nocarcinoma, paralleled by activation of its downstream
genes, such as GLUT1, vascular endothelial growth factor
(VEGF) and increased angiogenesis. These results high-
light the importance of hypoxia and related pathways in
the progression of endometrial carcinoma [49]; however,
there was a contradictory report on the expression of
GLUT1 under hypoxic conditions. In a series of studies,
Mayer et al. [50] examined the expression of HIF-1α and
GLUT1 in tissue micro-areas where direct O2 measure-
ments had previously been carried out, so that the influ-
ence of tumor heterogeneity could be reduced to a
minimum. Using this methodology, no correlation
between the expression of HIF-1α and GLUT1 and direct
pO2 measurements could be found.
Little is known about the details of CRC tumorigenesis.
Knowing how to rapidly organize new techniques for
exploring the prognosis is a key to providing physicians
with the information needed for further intervention. In
the present study, we found GLUT1 mRNA expression in
the peripheral blood of CRC patients. Advanced cancer
stage was significantly related to GLUT1 overexpression (P
= 0.004), the risk of which was higher in stages II and III
than in stage I (RR: 12.482; P = 0.001). GLUT1 overexpres-
sion in the blood also correlated with advanced tumor
stages. The GLUT1 overexpression rates for stages I, II and
III were 33.3%, 85.9% and 86.5%, respectively. This find-
ing suggests that GLUT1 may be a stage-related marker
that could be determined by a non-invasive method.
However, the low number of patients in stage I would be
over-interpreted according to the significant P value of
GLUT1 in Additional File 5. The additional glycolysis- and
hypoxia-associated gene expression data obtained from
peripheral blood showed that no statistical correlations
existed between CA9, CA12, COX-2, HIF-1α, and HIF-2α
overexpression and age or sex (P > 0.05). In 2008, Nguyen
et al. found that high correlations between the primary
tumours and metastatic lymph nodes in non-small-cell
lung cancer patients and the GLUT1 mediated fluorodeox-
yglucose (FDG) uptake may be useful for mediastinal
lymph nodes discrimination by fluorodeoxyglucose posi-
tron emission tomography (FDG-PET). It might be possi-
ble to combine GLUT1 with other new image diagnostic
techniques (e.g., FDG-PET) to interpret the clinical condi-
tion of tumours [51].
Conclusion
In conclusion, the levels of HIF-1α, HIF-2α, and the
GLUT1 genes were significantly overexpressed in CRC tis-
sue specimens, and the elevated ratio of GLUT1 was
greater in stage-III and -IV CRC tissue specimens than in
stage-I and -II specimens. The GLUT1 mRNA was also
more increased in the peripheral blood of stages-II and -
III CRC patients than in stage-I patients. The overexpres-
sion ratio of GLUT1 gene is higher in poorly differentiated
stage-III and -IV human CRC specimens. We postulate
that the overexpression of GLUT1 may play an important
role in the tumour progression of CRC. GLUT1 should be
considered to have potential carcinogenesis potency in
advanced human CRC. In further studies, GLUT1 expres-
sion should be investigated as a useful target for therapeu-
tic intervention. Future research will use this molecular
marker to identify those cancer patients who would
respond best to radiation therapy and chemotherapy,
thereby improving the clinical treatment outcome.
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